Construction of the plasmid coding for the expression of the EGFP‑M‑IL‑2(88Arg, 125Ala) fusion protein and the anti‑tumor effects exerted by the fusion protein in HeLa-60 cells
Corrigendum in: /10.3892/ol.2021.12623
- Authors:
- Published online on: April 20, 2015 https://doi.org/10.3892/ol.2015.3125
- Pages: 2729-2735
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
Gene therapy is a promising therapeutic option for the treatment of various cancers, and tumor‑targeted plasmids encoding toxic protein genes are potential tools for gene therapy. In the present study, a recombinant plasmid containing the genes for the toxic protein melittin and interleukin‑2 (IL‑2) was constructed. Melittin and IL‑2 are known to play key roles in immunoregulation and cancer therapy, but they each possess defects that limit the clinical application of these proteins. The present study aimed to construct a novel recombinant expression plasmid, pLEGFP‑C1‑M‑IL‑2(88Arg, 125Ala), and to improve the biological activity of IL‑2 and melittin. The M‑IL‑2(88Arg, 125Ala) gene was excised from the pPICZαA/M‑IL‑2(88Arg, 125Ala) plasmid by polymerase chain reaction (PCR). The pLEGFP‑C1 plasmid carrying the enhanced green fluorescent protein (EGFP) gene was used as a shuttle plasmid. Subsequent to digestion, the M‑IL‑2(88Arg, 125Ala) gene was subcloned into the pLEGFP‑C1 vector to build the pLEGFP‑C1‑M‑IL‑2(88Arg, 125Ala) eukaryotic expression plasmid, which was identified by restriction enzyme digestion and gene sequencing. Confocal microscopy was used to determine the transfection efficiency subsequent to the plasmid being transfected into the cervical cancer HeLa cell line. The cells transfected with the pLEGFP‑C1‑M‑IL‑2(88Arg, 125Ala) plasmid demonstrated a decreased transfection efficiency compared with the cells transfected with the pLEGFP‑C1 plasmid. The cellular expression of M‑IL‑2(88Arg, 125Ala) was detected by reverse transcription PCR and western blot analysis. Finally, cell counting kit‑8 and apoptosis assays were performed to investigate the effects of the expression of the M‑IL‑2(88Arg, 125Ala) fusion protein on HeLa cells and to analyze the antitumor activity of the protein. In conclusion, a recombinant eukaryotic pLEGFP‑C1‑M‑IL‑2(88Arg, 125Ala) expression plasmid containing the M‑IL‑2(88Arg, 125Ala) fusion gene was constructed and the M‑IL‑2(88Arg, 125Ala) fusion protein was successfully expressed in HeLa cells. Furthermore, the M‑IL‑2(88Arg, 125Ala) fusion protein was able to inhibit HeLa cell proliferation and induce apoptosis in the tumor cells. These findings may offer an alternative method for anticancer therapy. The present study has provided a basis for future studies into the M‑IL‑2(88Arg, 125Ala) fusion gene.
